Expression of p18INK4C is down-regulated in human pituitary adenomas

Endocrine Pathology

Volumn 20, Issue 2, 2009, Pages 114-121

  Hossain, Md Golam ^a   Iwata, Takeo ^a   Mizusawa, Noriko ^a   Qian, Zhi Rong ^a   Shima, Shahidan Wan Nazatul ^a   Okutsu, Toru ^a   Yamada, Shozo ^b   Sano, Toshiaki ^a   Yoshimoto, Katsuhiko ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b TORANOMON HOSPITAL   (Japan)

Author keywords

Cell cycle regulators; DNA methylation; INK4 family proteins; P18INK4C gene; Pituitary adenomas

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2C; MESSENGER RNA;

ADULT; AGED; ARTICLE; CARCINOGENESIS; DOWN REGULATION; FEMALE; GROWTH HORMONE SECRETING ADENOMA; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; NONFUNCTIONING PITUITARY ADENOMA; PRIORITY JOURNAL; PROLACTINOMA; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN METHYLATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TUMOR VOLUME; ADENOMA; DNA METHYLATION; GENE EXPRESSION REGULATION; GENETICS; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CYCLIN-DEPENDENT KINASE INHIBITOR P18; DNA METHYLATION; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MIDDLE AGED; MUTATION; PITUITARY NEOPLASMS; RNA, MESSENGER;

EID: 67651031247     PISSN: 10463976     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12022-009-9076-0     Document Type: Article

References (41)

1. Heaney AP, Melmed S. Molecular targets in pituitary tumours. Nat Rev Cancer 4:285-295, 2004. doi:10.1038/nrc1320
2. Asa SL, Ezzat S. The pathogenesis of pituitary tumours. Nat Rev Cancer 2:836-849, 2002. doi:10.1038/nrc926 (Pubitemid 37328902)
3. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Katsuragi K, Kinoshita M, Saito S, Itakura M. Ras mutations in endocrine tumors: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Jpn J Cancer Res 83:1057-1062, 1992.
4. Yoshimoto K, Iwahana H, Fukuda A, Sano T, Saito S, Itakura M. Role of p53 mutations in endocrine tumorigenesis: mutation detection by polymerase chain reaction-single strand conformation polymorphism. Cancer Res 52:5061-5064, 1992.
5. Tanaka C, Kimura T, Yang P, Moritani M, Yamaoka T, Yamada S, Sano T, Yoshimoto K, Itakura M. Analysis of loss of heterozygosity on chromosome 11 and infrequent inactivation of MEN1 gene in sporadic pituitary adenomas. J Clin Endocrinol Metab 83:2631-2634, 1998. doi:10.1210/jc.83.8.2631 (Pubitemid 28493752)
6. Yoshimoto K, Tanaka C, Moritani M, Shimizu E, Yamaoka T, Yamada S, Sano T, Itakura M. Infrequent detectable somatic mutations of the RET and glial cell line-derived neurotrophic factor (GDNF) genes in human pituitary adenomas. Endocr J 46:199-207, 1999. doi:10.1507/endocrj.46.199
7. Yamasaki H, Mizusawa N, Nagahiro S, Yamada S, Sano T, Itakura M, Yoshimoto K. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24. Clin Endocrinol 58:464-470, 2003. doi:10.1046/j.1365- 2265.2003.01740.x
8. Honda S, Tanaka-Kosugi C, Yamada S, Sano T, Matsumoto T, Itakura M, Yoshimoto K. Human pituitary adenomas infrequently contain inactivation of retinoblastoma 1 gene and activation of cyclin dependent kinase 4 gene. Endocr J 50:309-318, 2003. doi:10.1507/endocrj.50.309 (Pubitemid 36830008)
9. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R, Gündogdu S, De Menis E, Mäkinen MJ, Launonen V, Karhu A, Aaltonen LA. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 312:1228-1230, 2006. doi:10.1126/science.1126100 (Pubitemid 43801151)
10. Daly AF, Jaffrain-Rea A, Valdes-Socin H, Ciccarelli A, Rohmer V, Tamburrano G, Borson-Chazot C, Estour B, Ciccarelli E, Brue T, Ferolla P, Emy P, Colao A, De Menis E, Lecomte P, Penfornis F, Delemer B, Bertherat J, Wemeau JL, De Herder W, Archambeaud F, Stevenaert A, Calender A, Murat A, Cavagnini F, Beckers A. Aryl hydrocarbon receptor-interacting protein gene mutations in familial isolated pituitary adenomas: analysis in 73 families. J Clin Endocrinol Metab 92:1891-1896, 2007. doi:10.1210/jc.2006-2513 (Pubitemid 46997206)
11. Iwata T, Yamada S, Mizusawa N, Golam HM, Sano T, Yoshimoto K. The aryl hydrocarbon receptor-interacting protein gene is rarely mutated in sporadic GH-secreting adenomas. Clin Endocrinol 66:499-502, 2007.
12. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Prezant TR, Bronstein MD, Melmed S. Pituitary tumor transforming gene expression in pituitary adenomas. J Clin Endocrinol Metab 84:761-767, 1999. doi:10.1210/jc.84.2.761 (Pubitemid 29075718)
13. Qian ZR, Sano T, Asa SL, Yamada S, Horiguchi H, Tashiro T, Li CC, Hirokawa M, Kovacs K, Ezzat S. Cytoplasmic expression of fibroblast growth factor receptor-4 in human pituitary adenomas: relation to tumor type, size, proliferation, and invasiveness. J Clin Endocrinol Metab 89:1904-1911, 2004. doi:10.1210/jc.2003- 031489
14. Shapiro GI. Cyclin-dependent kinase pathways as targets for cancer treatment. J Clin Oncol 24:1770-1783, 2006. doi:10.1200/ JCO.2005.03.7689
15. Ortega S, Malumbres M, Barbacid M. Cyclin D-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602:73-87, 2002.
16. FarrellWE, Clayton RN. Epigenetic change in pituitary tumorigenesis. Endocr Relat Cancer 10:323-330, 2003. doi:10.1677/erc.0.0100323 (Pubitemid 36758658)
17. Yoshino A, Katayama Y, Ogino A, Watanabe T, Yachi K, Ohta T, Komine C, Yokoyama T, Fukushima T. Promoter hypermethylation profile of cell cycle regulator genes in pituitary adenomas. J Neuro-Oncol 83:153-162, 2007. doi:10.1007/s11060-006-9316-9 (Pubitemid 46784988)
18. Woloschak M, Yu A, Xiao J, Post KD. Frequent loss of the P16INK4a gene product in human pituitary tumors. Cancer Res 56:2493-2496, 1996.
19. Franklin DS, Godfrey VL, Lee H, Kovalev GI, Schoonhoven R, Chen-Kiang S, Su L, Xiong Y. CDK inhibitors p18INK4c and p27Kip1 mediate two separate pathways to collaboratively suppress pituitary tumorigenesis. Genes Dev 12:2899-2911, 1998. doi:10.1101/gad.12.18.2899
20. Bai F, Pei X, Pandolfi PP, Xiong Y. p18Ink4c and Pten constrain a positive regulatory loop between cell growth and cell cycle control. Mol Cell Biol 26:4564-4576, 2006. doi:10.1128/ MCB.00266-06
21. Bai F, Pei XH, Nishikawa T, Smith MD, Xiong Y. p18Ink4c, but not p27Kip1, collaborates with Men1 to suppress neuroendocrine organ tumors. Mol Cell Biol 27:1495-1504, 2007. doi:10.1128/ MCB.01764-06
22. Van Veelen W, Gasteren CJ, Action DS, Franklin DS, Berger R, Lips CJ, Höppener JW. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development. Cancer Res 68:1329-1337, 2008. doi:10.1158/0008-5472.CAN- 07-5754
23. Hardy J. Transsphenoidal microsurgical treatment of pituitary tumors. In: Linfoot JA, ed. Recent advances in the diagnosis and treatment of pituitary tumors. NY: Raven Press, 1979; 375-388.
24. Bartkova J, Thullberg M, Rajpert-De Meyts E, Skakkebaek NE, Bartek J. Cell cycle regulators in testicular cancer: loss of p18INK4C marks progression from carcinoma in situ to invasive germ cell tumours. Int J Cancer 85:370-375, 2000. doi:10.1002/ (SICI)1097-0215(20000201)85:3<370::AID-IJC13>3.0.CO;2-A
25. Sánchez-Aguilera A, Delgado J, Camacho FI, Sánchez-Beato M, Sánchez L, Montalbán C, Fresno MF, Martín C, Piris MA, García JF. Silencing of the p18INK4C gene by promoter hypermethylation in Reed-Sternberg cells in Hodgkin lymphomas. Blood 103:2351-2357, 2004. doi:10.1182/blood-2003-07-2356 (Pubitemid 38326257)
26. Morishita A, Masaki T, Yoshiji H, Nakai S, Ogi T, Miyauchi Y, Yoshida S, Funaki T, Uchida N, Kita Y, Funakoshi F, Usuki H, Okada S, Izuishi K, Watanabe S, Kurokohchi K, Kuriyama S. Reduced expression of cell cycle regulator p18INK4C in human hepatocellular carcinoma. Hepatology 40:677-686, 2004. doi:10.1002/hep.20337 (Pubitemid 39265590)
27. Uziel T, Zindy F, Xie S, Lee Y, Forget A, Magdaleno S, Rehg JE, Calabrese C, Solecki D, Eberhart CG, Sherr SE, Plimmer S, Clifford SC, Hatten ME, McKinnon PJ, Gilbertson RJ, Curran T, Sherr CJ, Roussel MF. The tumor suppressors Ink4c and p53 collaborate independently with Patched to suppress medulloblastoma formation. Genes Dev 19:2656-2667, 2005. doi:10.1101/gad.1368605 (Pubitemid 41627933)
28. Solomon DA, Kim JS, Jenkins S, Ressom H, Huang M, Coppa N, Mabanta L, Bigner D, Yan H, Jean W, Waldman T. Identification of p18INK4c as a tumor suppressor gene in glioblastoma multiforme. Cancer Res 68:2564-2569, 2008. doi:10.1158/0008-5472. CAN-07-6388
29. Kirsch M, Mörz M, Pinzer T, Schackert HK, Schackert G. Frequent loss of the CDKN2C (p18INK4c) gene product in pituitary adenomas. Genes Chromosomes Cancer 48:143-154, 2009. doi:10.1002/gcc.20621
30. Morris DG, Musat M, Czirják S, Hanzély Z, Lillington DM, Korbontís M, Grossman AB. Differential gene expression in pituitary adenomas by oligonucleotide array analysis. Eur J Endocrinol 153:143-151, 2005. doi:10.1530/eje.1.01937 (Pubitemid 41030525)
31. Esteller M. CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future. Oncogene 21:5427-5440, 2002. doi:10.1038/sj.onc.1205600 (Pubitemid 34983479)
32. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826, 1996. doi:10.1073/pnas.93.18.9821 (Pubitemid 26296693)
33. Shames DS, Minna JD, Gazdar AF. Methods for detecting DNA methylation in tumors: from bench to bedside. Cancer Lett 251:187-198, 2007. doi:10.1016/j.canlet.2006.10.014 (Pubitemid 46669792)
34. Frommer M, McDonald LE, Millar DS, Collis CM, Watt F, Grigg GW, Molloy PL, Paul CL. A genomic sequencing protocol that yields a positive display of 5-methylcytosines residues in individual DNA strands. Proc Natl Acad Sci USA 89:1827- 1831, 1992. doi:10.1073/pnas.89.5.1827
35. Blais A, Monte D, Pouliot F, Labrie C. Regulation of the human cyclin-dependent kinase inhibitor p18INK4c by the transcription factors E2F1 and Sp1. J Biol Chem 277:31679-31693, 2002. doi:10.1074/jbc.M204554200 (Pubitemid 34968972)
36. Tallack MR, Keys JR, Perkins AC. Erythroid krüppel-like factor regulates the G1 cyclin-dependent kinase inhibitor p18INK4c. J Mol Biol 369:313-321, 2007. doi:10.1016/j.jmb.2007.02.109 (Pubitemid 46678040)
37. Joshi PP, Kulkarni MV, Yu BK, Smith KR, Norton DL, Veelen W, Höppener JW, Franklin DS. Simultaneous downregulation of CDK inhibitors p18Ink4c and p27Kip1 is required for MEN2ARET- mediated mitogenesis. Oncogene 26:554-570, 2007. doi:10.1038/sj.onc.1209811 (Pubitemid 46160969)
38. Karnik SK, Hughes CM, Gu X, Rozenblatt-Rosen O, McLean GW, Xiong Y, Meyerson M, Kim SK. Menin regulates pancreatic islet growth by promoting histone methylation and expression of genes encoding p27Kip1 and p18INK4c. Proc Natl Acad Sci USA 102:14659-14664, 2005. doi:10.1073/pnas.0503484102 (Pubitemid 41457112)
39. Miller CW, Aslo A, Campbell MJ, Kawamata N, Lampkin BC, Koeffler HP. Alterations of the p15, p16, and p18 genes in osteosarcoma. Cancer Genet Cytogenet 86:136-142, 1996. doi:10.1016/0165-4608(95)00216-2 (Pubitemid 26074804)
40. Tahara H, Smith AP, Gaz RD, Zariwala M, Xiong Y, Arnold A. Parathyroid tumor suppressor on 1p: analysis of the p18 cyclindependent kinase inhibitor gene as a candidate. J Bone Miner Res 12:1330-1334, 1997. doi:10.1359/jbmr.1997. 12.9.1330 (Pubitemid 27375375)
41. Lindberg D, Akerstorm G, Westin G. Mutational analysis of p27 (CDKN1B) and p18 (CDKN2C) in sporadic pancreatic endocrine tumors argues against tumor-suppressor function. Neoplasia 9:533-535, 2007. doi:10.1593/neo.07328 (Pubitemid 47121826)